Scientific publications

Complementary chemotherapy of breast cancer; experience at the University Clinic of Navarra

Vieitez J.M., Martín Algarra S., Muñoz L., Fernández Hidalgo O., Herranz P., Azinovick I., Zornoza G.
Departamento de Oncología Médica, Clínica Universitaria de Navarra, Pamplona.

Magazine: Revista de Medicina de la Universidad de Navarra

Date: Jul 1, 1990

Breast Cancer Area Medical Oncology

From 1982 to 1989, 68 patients were treated with the diagnosis of breast cancer. 57 were premenopausal and 11 postmenopausal. The most frequent stage was T2N1 (44.1%) followed by T1N1 (20.6%). The mean dosage of chemotherapy given were 91.2% for cyclophosphamide, 88% for methotrexate and 94% for 5-fluorouracil. The treatment was well tolerated and the most frequent toxicity encountered was leukopenia. The disease free survival were 89.4% at 96 month for premenopausal and 63.3% at 68 month for postmenopausal.

We have not seen any differences in the disease free survival in relation to the size of the tumor or the status of the hormonal receptors of the tumor. The most important prognostic factor were the number of positive axilar nodes affected and the dosage of chemotherapy.

CITA DEL ARTÍCULO  Rev Med Univ Navarra. 1990 Jul-Sep;34(3):172-5

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra